Validation of the INNO-LiPA HBV DR Assay (version 2) in Monitoring Hepatitis B Virus-infected Patients Receiving Nucleoside Analog Treatment

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2010 Jan 13

PMID 20065049

Citations 8

Authors

H G M Niesters

F Zoulim

C Pichoud

M Buti

F Shapiro

N DHeuvaert

L Celis

J Doutreloigne

E Sablon

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV) antiviral drug resistance mutations prevent successful outcome of treatment and lead to worsening of liver disease. Detection of its emergence permits opportune treatment with alternative drugs. Unfortunately, the use of newly approved antivirals, including adefovir dipivoxil, emtricitabine, and telbivudine, is also associated with the development of drug resistance, albeit to a lesser extent than the use of lamivudine. The objectives of this work were to assess the performance characteristics (sensitivity and accuracy) of an updated drug resistance test, the INNO-LiPA HBV DR v2, which includes detection of mutations associated with lamivudine, adefovir, emtricitabine, and telbivudine resistance, and to compare the results with consensus sequencing of serum samples from patients treated with HBV antivirals. Diagnostic sensitivity, defined as detection of a positive amplification line on the line probe assay (LiPA) strip, was 94.8% (95% confidence interval [CI], 89.7 to 97.9) after initial testing, increasing to 96.3% (95% CI, 91.6 to 98.8) after repeat test 1 and to 100% (95% CI, 97.3 to 100.0) after repeat test 2. In diagnostic accuracy determinations, full concordance was observed between sequencing and LiPA for 77.0% of the codons tested (620/805 codons [95% CI, 74.0 to 79.9]), whereas LiPA and sequencing were partially concordant 22% of the time (177/805 codons). In 167 out of 177 cases, LiPA detected a wild-type/mutant mixture whereas sequencing detected only one of the two results. Performance testing of the new LiPA test, the INNO-LiPA HBV DR v2, showed convincing diagnostic sensitivity and accuracy. The ability of the test to detect mixed infections and minority viral populations associated with resistance to the current generation of antivirals, including adefovir, emtricitabine, and telbivudine, makes it a useful tool for HBV therapy monitoring.

Citing Articles

De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.

Yang S, Xing H, Wang Q, Wang X, Liu S, Cheng J Ann Clin Microbiol Antimicrob. 2016; 15:24.

PMID: 27079793 PMC: 4832522. DOI: 10.1186/s12941-016-0138-0.

Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.

Zhang X, Li M, Cao Y, Zhang R, Zhang Y, Li F Medicine (Baltimore). 2016; 95(4):e2614.

PMID: 26825915 PMC: 5291585. DOI: 10.1097/MD.0000000000002614.

Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory.

Lowe C, Merrick L, Harrigan P, Mazzulli T, Sherlock C, Ritchie G J Clin Microbiol. 2015; 54(1):127-33.

PMID: 26537448 PMC: 4702765. DOI: 10.1128/JCM.02229-15.

Hepatitis B virus compartmentalization in the cerebrospinal fluid of HIV-infected patients.

Ene L, Duiculescu D, Tardei G, Ruta S, Smith D, Mehta S Clin Microbiol Infect. 2015; 21(4):387.e5-8.

PMID: 25658525 PMC: 4424164. DOI: 10.1016/j.cmi.2014.11.012.

Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus.

Wong D, Tsoi O, Huang F, Seto W, Fung J, Lai C J Clin Microbiol. 2014; 52(9):3209-15.

PMID: 24951803 PMC: 4313139. DOI: 10.1128/JCM.00343-14.

References

Honkoop P, de Man R, Niesters H, Zondervan P, Schalm S . Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000; 32(3):635-9. DOI: 10.1053/jhep.2000.16333. View

Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6):1743-51. DOI: 10.1053/j.gastro.2006.09.020. View

Lok A, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H . Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol. 2002; 40(10):3729-34. PMC: 130856. DOI: 10.1128/JCM.40.10.3729-3734.2002. View

Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P . Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol. 2006; 44(3):1094-7. PMC: 1393162. DOI: 10.1128/JCM.44.3.1094-1097.2006. View

Lai C, Chien R, Leung N, Chang T, Guan R, Tai D . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998; 339(2):61-8. DOI: 10.1056/NEJM199807093390201. View

Degertekin B, Hussain M, Tan J, Oberhelman K, Lok A . Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol. 2008; 50(1):42-8. DOI: 10.1016/j.jhep.2008.08.020. View

Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve J, Trepo C . Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007; 46(3):531-8. DOI: 10.1016/j.jhep.2006.11.016. View

Leung N, Lai C, Chang T, Guan R, Lee C, Ng K . Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001; 33(6):1527-32. DOI: 10.1053/jhep.2001.25084. View

Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney 4th W . Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005; 10(5):625-33. View

10.

Southern E, Mir K, Shchepinov M . Molecular interactions on microarrays. Nat Genet. 1999; 21(1 Suppl):5-9. DOI: 10.1038/4429. View

11.

Lai C, Leung N, Teo E, Tong M, Wong F, Hann H . A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129(2):528-36. DOI: 10.1016/j.gastro.2005.05.053. View

12.

Aberle S, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E . Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol. 2001; 39(5):1972-4. PMC: 88061. DOI: 10.1128/JCM.39.5.1972-1974.2001. View

13.

Lim S, Ng T, Kung N, Krastev Z, Volfova M, Husa P . A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006; 166(1):49-56. DOI: 10.1001/archinte.166.1.49. View

14.

Brunelle M, Jacquard A, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve J . Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005; 41(6):1391-8. DOI: 10.1002/hep.20723. View

15.

Lai C, Dienstag J, Schiff E, Leung N, Atkins M, Hunt C . Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003; 36(6):687-96. DOI: 10.1086/368083. View

16.

Yim H, Hussain M, Liu Y, Wong S, Fung S, Lok A . Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006; 44(3):703-12. DOI: 10.1002/hep.21290. View

17.

Dienstag J, Schiff E, Wright T, Perrillo R, Hann H, Goodman Z . Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17):1256-63. DOI: 10.1056/NEJM199910213411702. View

18.

Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M . Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005; 42(6):1414-9. DOI: 10.1002/hep.20939. View

19.

Hadziyannis S, Papatheodoridis G, Dimou E, Laras A, Papaioannou C . Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000; 32(4 Pt 1):847-51. DOI: 10.1053/jhep.2000.17915. View

20.

Liaw Y, Chien R, Yeh C, Tsai S, Chu C . Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999; 30(2):567-72. DOI: 10.1002/hep.510300221. View